This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
1 “In line with the goals of its Immunization Agenda 2030, WHO has identified a new list of 17 high-priority global endemic pathogens for vaccine research and development, of which skin pathogens account for at least 8, reinforcing the need for continued focus in this area.” References 1. Goh E, Chavatte JM, Lin RTP, et al.
James Stevenson PharmD, FASHP, Chief Clinical Officer, Omnicell The United States faces a shortage of physicians – expected to reach approximately 139,000 by 2030. Pharmacist provider status would align reimbursement with pharmacists' services and give underserved patients more access to crucial care.
According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This equates to approximately doubling the current medical workforce.
"Mavyret has treated more than 1 million patients with HCV, but we recognize that a significant need remains for patients with acute infection," Roopal Thakkar, MD, executive vice president of research and development and chief scientific officer at AbbVie, said in a release. References 1.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content